Actavis: Clinical trial disclosure query for Zinforo/Teflaro ruled outwith PMCPA scope (AUTH/2772/6/15)

📊

Key facts

⌄

Case number	AUTH/2772/6/15
Parties	Paragraph 5.1/Director v Actavis
Issue	Clinical trial disclosure (Zinforo (marketed as Teflaro in USA))
Complaint received	11 June 2015
Completed	10 July 2015
Applicable Code year	2015
Decision	No breach; outwith the scope of the Code
Report status	No case report as outwith the scope of the Code
Sanctions	None stated

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

A matter was raised under Paragraph 5.1 by the PMCPA Director against Actavis.
The issue related to clinical trial disclosure for Zinforo (marketed as Teflaro in the USA).
The PMCPA determined the matter was outwith the scope of the ABPI Code of Practice.

⚖️

⌄

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →